| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| I M Holdaway, M J Bolland, G D Gambl. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European journal of endocrinology. vol 159. issue 2. 2008-08-19. PMID:18524797. |
a meta-analysis of the effect of lowering serum levels of gh and igf-i on mortality in acromegaly. |
2008-08-19 |
2023-08-12 |
Not clear |
| I M Holdaway, M J Bolland, G D Gambl. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European journal of endocrinology. vol 159. issue 2. 2008-08-19. PMID:18524797. |
formal studies of acromegaly have found increased mortality associated with the disorder, although reduction of serum levels of gh and igf-i by treatment appears to improve survival. |
2008-08-19 |
2023-08-12 |
Not clear |
| I M Holdaway, M J Bolland, G D Gambl. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European journal of endocrinology. vol 159. issue 2. 2008-08-19. PMID:18524797. |
a meta-analysis of mortality studies in acromegaly has thus been performed to assess the effect of lowering serum gh and igf-i on survival. |
2008-08-19 |
2023-08-12 |
Not clear |
| S F M Bhatti, L Duchateau, A C Okkens, L M L Van Ham, J A Mol, H S Kooistr. Treatment of growth hormone excess in dogs with the progesterone receptor antagonist aglépristone. Theriogenology. vol 66. issue 4. 2008-08-13. PMID:16497368. |
acromegaly or hypersomatotropism in dogs is almost always due to progestin-induced hypersecretion of gh originating from the mammary gland. |
2008-08-13 |
2023-08-12 |
Not clear |
| Philippe Chanson, Sylvie Salenav. Acromegaly. Orphanet journal of rare diseases. vol 3. 2008-08-11. PMID:18578866. |
acromegaly is an acquired disorder related to excessive production of growth hormone (gh) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. |
2008-08-11 |
2023-08-12 |
Not clear |
| Philippe Chanso. Emerging drugs for acromegaly. Expert opinion on emerging drugs. vol 13. issue 2. 2008-08-04. PMID:18537521. |
acromegaly is due to growth hormone (gh) hypersecretion by a benign pituitary tumor (adenoma). |
2008-08-04 |
2023-08-12 |
Not clear |
| Fabrícia Torres Gonçalves, Taciana C Maia Feibelmann, Maria Luiza M P Fernandes, Alessandra R C Fonseca, Henrique Pierotti Arantes, Paulo Tannús Jorg. [Discrepancy between IGF-1 and GH during 75 g oral glucose tolerance test measures to acromegaly screening in a patient with macroprolactinoma--case report and literature review]. Arquivos brasileiros de endocrinologia e metabologia. vol 51. issue 3. 2008-07-31. PMID:17546251. |
[discrepancy between igf-1 and gh during 75 g oral glucose tolerance test measures to acromegaly screening in a patient with macroprolactinoma--case report and literature review]. |
2008-07-31 |
2023-08-12 |
Not clear |
| Fabrícia Torres Gonçalves, Taciana C Maia Feibelmann, Maria Luiza M P Fernandes, Alessandra R C Fonseca, Henrique Pierotti Arantes, Paulo Tannús Jorg. [Discrepancy between IGF-1 and GH during 75 g oral glucose tolerance test measures to acromegaly screening in a patient with macroprolactinoma--case report and literature review]. Arquivos brasileiros de endocrinologia e metabologia. vol 51. issue 3. 2008-07-31. PMID:17546251. |
after the development of new more sensitive gh assays, cases of discrepant gh and igf-1 results have been observed and taken to some authors to suggest that gh nadir concentration during 75 g ogtt used to acromegaly diagnosis and treatment could be lower than values considered currently normal. |
2008-07-31 |
2023-08-12 |
Not clear |
| Alessandra Casagrande, Mauro A Czepielewsk. [Growth hormone (GH) and IGF-I assays: methodological aspects and its implications in acromegaly diagnosis and follow-up]. Arquivos brasileiros de endocrinologia e metabologia. vol 51. issue 4. 2008-07-31. PMID:17684610. |
[growth hormone (gh) and igf-i assays: methodological aspects and its implications in acromegaly diagnosis and follow-up]. |
2008-07-31 |
2023-08-12 |
Not clear |
| Alessandra Casagrande, Mauro A Czepielewsk. [Growth hormone (GH) and IGF-I assays: methodological aspects and its implications in acromegaly diagnosis and follow-up]. Arquivos brasileiros de endocrinologia e metabologia. vol 51. issue 4. 2008-07-31. PMID:17684610. |
the importance of adequate treatment is highlighted by data indicating that lowering gh levels to less than 2.5 microg/l reverses the premature mortality of acromegaly. |
2008-07-31 |
2023-08-12 |
Not clear |
| Alessandra Casagrande, Mauro A Czepielewsk. [Growth hormone (GH) and IGF-I assays: methodological aspects and its implications in acromegaly diagnosis and follow-up]. Arquivos brasileiros de endocrinologia e metabologia. vol 51. issue 4. 2008-07-31. PMID:17684610. |
in this review, we describe the changes of assay methodology and its consequences in serum gh results and cut off point values to define activity and remission of acromegaly. |
2008-07-31 |
2023-08-12 |
Not clear |
| R I G Holt, P H Sönkse. Growth hormone, IGF-I and insulin and their abuse in sport. British journal of pharmacology. vol 154. issue 3. 2008-07-31. PMID:18376417. |
the effects of excess gh are exemplified by acromegaly. |
2008-07-31 |
2023-08-12 |
human |
| Pamela U Freda, Wei Shen, Steven B Heymsfield, Carlos M Reyes-Vidal, Eliza B Geer, Jeffrey N Bruce, Dympna Gallaghe. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. The Journal of clinical endocrinology and metabolism. vol 93. issue 6. 2008-07-17. PMID:18349062. |
in acromegaly, a state of gh and igf-i excess, the lipolytic and insulin antagonistic effects of gh may alter adipose tissue (at) distribution. |
2008-07-17 |
2023-08-12 |
Not clear |
| Annamaria Colao, Josef Marek, Miklos I Goth, Philippe Caron, Jean Marc Kuhn, Francesco M Minuto, Neil J Weissma. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. The Journal of clinical endocrinology and metabolism. vol 93. issue 6. 2008-07-17. PMID:18381583. |
excess gh and igf-i in acromegaly are associated with reduced life expectancy due to cardiovascular complications. |
2008-07-17 |
2023-08-12 |
Not clear |
| Ayman M Arafat, Matthias Möhlig, Martin O Weickert, Frank H Perschel, Johannes Purschwitz, Joachim Spranger, Christian J Strasburger, Christof Schöfl, Andreas F H Pfeiffe. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. The Journal of clinical endocrinology and metabolism. vol 93. issue 4. 2008-05-27. PMID:18171702. |
besides the measurement of igf-i, gh suppression during an oral glucose tolerance test is recommended to assess the biochemical status in acromegaly. |
2008-05-27 |
2023-08-12 |
Not clear |
| Stine Lyngvi Fougner, Jens Bollerslev, Fahim Latif, John K Hald, Terje Lund, Jon Ramm-Pettersen, Jens Petter Ber. Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. The Journal of clinical endocrinology and metabolism. vol 93. issue 4. 2008-05-27. PMID:18230656. |
excessive gh production by pituitary tumors causes acromegaly. |
2008-05-27 |
2023-08-12 |
Not clear |
| S L Lau, S McGrath, D Evain-Brion, R Smit. Clinical and biochemical improvement in acromegaly during pregnancy. Journal of endocrinological investigation. vol 31. issue 3. 2008-05-22. PMID:18401209. |
numerous case reports of pregnancy in acromegaly exist, however detailed descriptions of changes in placental and pituitary gh and igf-i throughout gestation are rare. |
2008-05-22 |
2023-08-12 |
Not clear |
| S L Lau, S McGrath, D Evain-Brion, R Smit. Clinical and biochemical improvement in acromegaly during pregnancy. Journal of endocrinological investigation. vol 31. issue 3. 2008-05-22. PMID:18401209. |
further surgical and medical therapies for acromegaly failed to normalize nonpregnant gh or igf-i levels in this woman. |
2008-05-22 |
2023-08-12 |
Not clear |
| Siobhan Loeper, Shereen Ezza. Acromegaly: re-thinking the cancer risk. Reviews in endocrine & metabolic disorders. vol 9. issue 1. 2008-04-30. PMID:18157698. |
acromegaly is characterized by sustained elevation of circulating growth hormone (gh) and insulin-like growth factor i (igf-i), and is clearly associated with increased morbidity and overall mortality mainly due to cardiovascular, metabolic, and respiratory diseases. |
2008-04-30 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Rosario Pivonello, Mariano Galdiero, Gaetano Lombard. Medical consequences of acromegaly: what are the effects of biochemical control? Reviews in endocrine & metabolic disorders. vol 9. issue 1. 2008-04-30. PMID:18163212. |
acromegaly results in premature death because of prolonged elevation of gh an igf-i levels, and a strong biochemical control improves well-being and restores life expectancy to normal. |
2008-04-30 |
2023-08-12 |
Not clear |